Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel diseaseJ Schultheiss, Bas Oldenburg, Remi Mahmoud et al.|Alimentary Pharmacology & Therapeutics|2021Cited by 49
Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, P van Boeckel et al.|Clinical Gastroenterology and Hepatology|2022Cited by 31
P414 Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseRemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Journal of Crohn s and Colitis|2021Cited by 3
721: IMMUNOMODULATOR WITHDRAWAL FROM ANTI-TNF THERAPY IS NOT ASSOCIATED WITH LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASERemi Mahmoud, Bas Oldenburg, J Schultheiss et al.|Gastroenterology|2022Cited by 0
P299 Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel DiseaseJ Schultheiss, Bas Oldenburg, J Louwers et al.|Journal of Crohn s and Colitis|2021Cited by 0